Inducing protein-protein interactions with molecular glues.
Ye Che, Adam M Gilbert, Veerabahu Shanmugasundaram, Mark C Noe
Author Information
Ye Che: Discovery Sciences, Medicine Design, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, CT 06340, United States.
Adam M Gilbert: Discovery Sciences, Medicine Design, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, CT 06340, United States.
Veerabahu Shanmugasundaram: Discovery Sciences, Medicine Design, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, CT 06340, United States.
Mark C Noe: Discovery Sciences, Medicine Design, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, CT 06340, United States. Electronic address: mark.c.noe@pfizer.com.
The drugable proteome is limited by the number of functional binding sites that can bind small molecules and respond with a therapeutic effect. Orthosteric and allosteric modulators of enzyme function or receptor signaling are well-established mechanisms of drug action. Drugs that perturb protein-protein interactions have only recently been launched. This approach is more difficult due to the extensive contact surfaces that must be perturbed antagonistically. Compounds that promote novel protein-protein interactions promise to dramatically expand opportunities for therapeutic intervention. This approach is precedented with natural products (rapamycin, FK506, sanglifehrin A), synthetic small molecules (thalidomide and IMiD derivatives) and indisulam analogues.
